This memo highlights the benefits, market considerations, and potential for savings of three ARV optimization opportunities.
Proactively switch eligible adult second-line patients on protease inhibitors to DTG-based regimens
Ensure transition of pediatric patients to appropriate optimal products as they age and grow
Move to larger, carton-less pack sizes to enable multi-month dispensing